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Abstract
Study Objectives: To ascertain whether current diagnostic criteria for REM sleep behavior disorder (RBD) are appropriate in patients with Parkinson’s disease 
(PD) consulting a movement disorder center, to evaluate the accuracy of REM sleep without atonia (RSWA) thresholds and determine the value of screening 
questionnaires to discriminate PD patients with RBD.
Methods: One hundred twenty-eight consecutive PD patients (M = 80; mean age: 65.6 ± 8.3 years) underwent screening questionnaires, followed by a sleep-focused 
interview and a full-night video-polysomnography (vPSG). Without a gold standard, latent class models (LCMs) were applied to create an unobserved (“latent”) 
variable. Sensitivity analysis was performed using RSWA cutoff derived from two visual scoring methods. Finally, we assessed the respective diagnostic performance 
of each diagnostic criterion for RBD and of the screening questionnaires.
Results: According to the best LCM-derived model, patients having either “history” or “video” with RSWA or alternatively showing both “history” and “video” without 
RSWA were classified as having RBD. Using both SINBAR and Montreal scoring methods, RSWA criterion showed the highest sensitivity while concomitant history of 
RBD and vPSG-documented behaviors, regardless to presence of RSWA, displayed the highest specificity. Currently recommended diagnostic threshold of RSWA was 
found to be optimal in our large cohort of PD patients. Both the RBD screening questionnaire (RBDSQ) and the RBD single question (RBD1Q) showed poor sensitivity 
and specificity.
Conclusions: Results of the best LCM for diagnosis of RBD in PD were consistent with the current diagnostic criteria. Moreover, RBD might be considered in those PD 
patients with both history and vPSG-documented dream enactment behaviors, but with RSWA values within the normal range.
Key words:  REM sleep behavior disorder; Parkinson’s disease; diagnostic criteria
Statement of Significance
REM sleep behavior disorder (RBD) in Parkinson’s disease (PD) is associated to a malignant phenotype. Despite its prognostic value, the 
diagnosis of RBD in PD may be challenging. Screening questionnaires and current diagnostic criteria, including quantification of REM sleep 
without atonia (RSWA), have been mainly defined in idiopathic RBD population. Using a latent-class model analysis approach, we found 
that current diagnostic criteria for RBD are appropriate in PD population and that patients with both history and video-polysomnography 
(vPSG)-documented dream enactment behaviors, but with RSWA values within the normal range, might be considered as full-blown RBD. 
Receiver operating characteristic (ROC) curve analysis showed that the cutoff of RSWA suggested by the International Classification of Sleep 
Disorders-third edition (ICSD-3) was optimal in our large cohort of PD patients. Conversely, RBD screening questionnaires showed limited 
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Introduction
Up to 42% of patients with Parkinson’s disease (PD) have REM 
sleep behavior disorder (RBD) [1, 2], a parasomnia character-
ized by loss of normal muscle atonia during REM sleep associ-
ated with dream-enacting behaviors [3, 4]. Increasing evidences 
show that RBD in PD is a marker of a more widespread and ag-
gressive neurodegenerative process [5], associated with a ma-
lignant clinical phenotype [6–8]. Indeed, PD patients with RBD 
(PDRBD+) tend to have more rigid akinetic forms, axial symp-
toms, and levodopa-induced dyskinesia [9–11]. These patients 
also have increased autonomic dysfunction [11, 12], more severe 
neuropsychiatric comorbidities, cognitive deficits, and an in-
creased risk of dementia [13–18]. Thus, the correct identification 
of RBD in PD may potentially bear therapeutic and prognostic 
implication.
The diagnosis of RBD relies on a history of dream enactment 
behaviors and the presence of specific video-polysomonograhy 
(vPSG) features. Indeed, diagnostic criteria for RBD according to 
the International Classification of Sleep Disorders-third edition 
published in 2014 (ICSD-3) [19] are the following: (1) the pres-
ence of repeated episodes of sleep-related vocalization and/or 
complex motor behaviors; (2) these behaviors are documented 
by vPSG to occur during REM sleep or, based on clinical history 
of dream enactment, are presumed to occur during REM sleep; 
(3) polysomnographic recording has to demonstrate REM sleep 
without atonia (RSWA) that exceed normal values; and (4) the 
disturbance is not better explained by another sleep disorder, 
mental disorder, medication, or substance use.
Although there are several methods to quantify RSWA, the 
American Academy of Sleep Medicine (AASM) in the ICSD-3 re-
cently suggested a cutoff derived from the SINBAR method as 
the most current evidence-based data for detecting RSWA in 
the evaluation of RBD, reliably distinguishing RBD patients from 
controls [19]. Based on these methods, RSWA is defined as ≥27% 
of 30-s epochs of REM sleep, with any (tonic/phasic) chin elec-
tromyographic (EMG) activity combined with bilateral phasic ac-
tivity of the flexor digitorum superficialis (FDS) muscles. A 30-s 
epoch is considered with RSWA if >3-s five mini-epochs are con-
taining RSWA [20–23].
Beside the diagnosis of full RBD, the most recent ICSD-3 also 
proposes that those patients who may have a typical clinical 
history of RBD and/or exhibit dream-enacting behaviors during 
vPSG, but do not fulfill the PSG criterion of RSWA may be provi-
sionally diagnosed with RBD, based on clinical judgment.
Anecdotally, RBD manifestations in PD are often milder than 
those seen in idiopathic RBD (I-RBD) and may include twitching 
or jerk-like movements, or simple vocalizations, that can go un-
noticed by both patient and bed partner. This could be due to 
a peculiar RBD phenotype in PD, as it has been observed that 
RBD in PD would be characterized by more “tonic” rather than 
phasic EMG activity [24]. However, a referral bias has also been 
suggested, since more complex and violent behaviors in I-RBD 
patients may lead to medical attention, while simple and milder 
behaviors may not. Moreover, PD patients are eventually diag-
nosed with RBD, even in case of milder forms, because they are 
already being cared of their PD by neurologists who may ask 
specifically about their sleep status.
Given these premises, the diagnosis of RBD in PD is often 
challenging, especially in milder forms. On the other hand, 
ICDS-3 diagnostic criteria for RBD have been mainly established 
based on the clinical features of I-RBD patients. This is espe-
cially true for the RSWA diagnostic cutoff, that has been estab-
lished based on norms including only small number (n = 15) of 
PD patients [20].
Finally, diagnosis of RBD requires vPSG, which is an expen-
sive and time-consuming procedure requiring specific expertise, 
not always available in clinical or research settings, especially 
in the field of epidemiological research. For this reason, sev-
eral screening questionnaires for RBD have been developed, 
including the most used RBD screening questionnaire (RBDSQ) 
and RBD single question (RBD1Q). However, these tools have 
been mainly validated in I-RBD population or in small cohort of 
PD patients [25–29].
This study is divided in three parts. First, we aimed to as-
certain whether current ICSD-3 diagnostic criteria for RBD are 
appropriate in PD population and to assess the respective role 
of each single criterion, in a large cohort of PD patients con-
secutively seen in a Movement Disorder Center and undergoing 
a vPSG assessment, by means of a latent-class model (LCM) 
analysis.
Secondly, we wished to assess whether the cutoff for RSWA 
selected by the AASM, reliably distinguish PD patients with both 
history of dream enactment behaviors and vPSG-documented 
motor behaviors from those without.
Finally, we aimed to assess the sensitivity and specificity of 
two RBD screening questionnaires, namely the RBD1Q [25] and 
the RBDSQ [26], in the same large cohort of consecutive PD pa-




One hundred twenty-eight (80 male, mean age 65.6 ± 8.3 years) 
nondemented PD patients consecutively seen for their routine 
evaluation at three Movement Disorder Center, namely the 
University Hospital in Clermont-Ferrand, France (n  =  100), the 
University Hospital in Cagliari, Italy (n = 18), and “Le Molinette” 
University Hospital in Turin, Italy (n  =  10) were recruited. 
Seventy-three of these patients were part of a recently pub-
lished report [24].
Inclusion criterion was the clinical diagnosis of PD according 
to United Kingdom Brain Bank Criteria [30]. Exclusion criteria 
were the presence of other causes of parkinsonism, clinically 
defined dementia according to the Diagnostic Statistical Manual 
V (DSM-V) criteria [31], psychosis according to DSM-V [31], the 
use of device-aided therapy, like subcutaneous Apomorphine 
infusion, intra-duodenal gel infusion, or deep brain stimula-
tion, and untreated obstructive sleep apnea syndrome with an 
apnea/hypopnea index (AHI) ≥15/h.
Demographic and clinical data, such as sex, age, PD duration, 
PD severity as measured by both the Hoehn & Yahr scale (HY) 
[32] and the Unified Parkinson’s disease rating scale (UPDRS), 
global cognitive function as assessed by the Montreal Cognitive 
Assessment (MoCA), and current antiparkinsonian treatment 
dose, were collected for all patients by a neurologist expert in 
movement disorders (A.R.M., F.D., M.M., M.Z., L.L.). The use of se-
lective serotonin/noradrenaline reuptake inhibitors (SSRI/SNRI), 
tricyclic antidepressant, benzodiazepines, and beta-blockers 
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and the dopamine agonist levodopa equivalent daily dose 
(DA-LEDD) were calculated according to Tomlinson et al. [33].
A detailed sleep-focused interview, including history of 
parasomnia, was performed by a neurologist expert in sleep 
medicine (M.L.F., M.F., M.P., A.C.).
Twenty-five age- and sex-matched control subjects without 
vPSG abnormalities were enrolled (12 male, mean age 61.5 ± 
13.7  years). They were addressed for sleep complaints such 
as insomnia, suspected obstructive sleep apnea syndrome 
(OSAS), or hypersomnia (n  =  14 in University Hospital in 
Clermont-Ferrand, France and n = 11 at University Hospital in 
Cagliari, Italy) but they show no anomalies on vPSG. Inclusion 
criteria for controls were age 40–85  years. Exclusion criteria 
were presence of neurological disease and current or past 
treatment with antipsychotic or antidepressant drugs. None 
of the controls was taking benzodiazepines, clonazepam, nor 
melatonin. All controls underwent an in-depth sleep-focused 
interview and v-PSG recording. The notion of the presence of a 
bed partner was also recorded in both groups.
The local ethical committees of each center approved the 
study and all participants gave written informed consent, ac-
cording to the Declaration of Helsinki.
Screening questionnaire
All patients fulfilled the RBD1Q and the RBDSQ prior to clinical 
interview. The RBD1Q is a single, “yes or no,” question that con-
cerns the dream enactment behavior of RBD: “Have you ever 
been told, or suspected yourself, that you seem to ‘act out your 
dreams’ while asleep (for example: punching, flailing your arms 
in the air, making running movements, etc.)?” [25].
The RBDSQ is a 10-item patient self-rating questionnaire, 
with “yes” or “no” questions, with a maximum score of 13 points, 
covering the clinical features of RBD [26]. In general popula-
tion, a cutoff value of ≥5 has shown a sensitivity of 96% and 
specificity of 56%, correctly diagnosing 66% of I-RBD subjects 
[26]. A cutoff value ≥6 was proposed for PD subjects because of 
item 10 assessing the presence of a comorbid Central Nervous 
System (CNS) disease is always scored yes in these patients [34].
Polysomnographic recording
All participants underwent one full-night attended vPSG re-
cording in sleep laboratory with digital polysomnography 
(Micromed, System Plus Evolution in all of the three centers), 
according to the AASM recommendations [35]. They were moni-
tored with infrared video recording synchronized with PSG. 
For both patients and healthy controls, the following montage 
was used: electroencephalographic leads (F3-A2, F4-A1, C3-A2, 
C4-A1, O1-A2, O2-A1), left and right electrooculography (EOG) 
channels, bilateral surface EMG channels (submentalis, FDS on 
upper limbs, tibialis anterior on lower limbs), and electrocardi-
ography. The respiratory analysis included nasal thermistor and 
nasal pressure sensor, thoracic and abdominal respiratory ef-
fort, pulse oxymeter, and microphone.
Patients had imposed time in bed (TIB) of approximately 8 h, 
light-off was set between 22:30 and 23:00 and light-on between 
06:30 and 07:00. In order to increase the detection of motor ac-
tivity, all participants slept uncovered, even if a light sheet could 
be allowed for their comfort.
Sleep stages were scored according to AASM criteria [35], 
with allowance to chin EMG tone during REM sleep. The fol-
lowing sleep data were collected: total bed time, total sleep 
time, sleep efficiency, sleep latency, wake after sleep onset 
(WASO), number of REM sleep episode, percentage of time 
in each sleep stage (N1, N2, N3, R), arousal index, periodic 
limb movements index (PLMS-i), AHI, oxygen-desaturation 
index (ODI).
RSWA was assessed in patients having spent ≥5 min in REM 
sleep, since shorter duration was believed to be insufficient for 
a reliable assessment of this parameter [24]. RSWA was manu-
ally quantified according to two previously published methods, 
namely the Montréal [36, 37], adapted to 30-s epochs [38], and 
the SINBAR method [20, 22, 23]. REM sleep epochs were carefully 
inspected for artifacts, such as increased muscle tone caused 
by respiratory arousal. The background EMG activity for each 
participant was considered as the minimum EMG amplitude ob-
served during REM sleep in the same patient.
The EMG signal was analyzed in all channels using 5 μV/mm 
amplification, 10–100 Hz band-pass filter, a sample rate of 256 
Hz, with a notch filter at 50 Hz.
According to the Montréal method, adapted to 30-s epochs, 
each epochs was scored as “tonic” if more than 50% of the 30-s 
epoch contained increased sustained EMG activity, with an 
amplitude at least twice the background EMG muscle tone, or 
more than 10 µV [37, 38]. Phasic chin EMG density was the per-
centage of 2-s mini-epochs containing EMG events lasting 0.1 
to 10 s, with amplitude exceeding four times the amplitude of 
background activity [36–38].
As reported by previous findings, RSWA was defined if ≥30% 
of 30-s REM sleep epochs contains tonic chin EMG activity and/
or ≥15% of 2-s REM sleep mini-epochs contains phasic chin ac-
tivity [36–38].
On the other hand, the SINBAR method scored each epoch 
as “tonic” referring to the Montréal method, but phasic activity 
was scored into 3-s mini-epochs and was defined as any burst 
of EMG activity lasting 0.1 to 5 s with an amplitude exceeding 
twice the background activity [20, 22, 23]. Moreover, phasic chin 
EMG activity superimposed on a background of tonic activity, 
during a 3-s mini-epoch, must show at least twice the ampli-
tude of the background activity within the same 3-s mini-epoch. 
Furthermore, each 3-s mini-epoch was scored as having or not 
“any” chin EMG activity, when containing either tonic and/or 
phasic EMG activity within the same mini-epoch. Tonic EMG ac-
tivity was scored only in the chin muscle, while phasic activity 
was assessed in both chin and bilateral FDS muscles. According 
to this method [20, 22, 23], RSWA was defined by presence of 
≥27% of 30-s REM sleep epochs containing any (either tonic or 
phasic) chin EMG activity combined with phasic EMG activity at 
bilateral FDS muscles (“any chin + FDS 30-s”), as suggested by 
the ICSD-3 edition [19].
The visual scoring of RSWA for all patients was performed by 
the same neurologist expert in sleep medicine (M.F.), who was 
blinded to RBD history.
Statistical analysis
Statistical analysis was performed using Stata software, ver-
sion 13 (StataCorp, College Station, TX) and R 3.3.3 (http://cran.r-
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0.05. Continuous data were expressed as means and standard 
deviations (SD), and categorical parameters as frequencies and 
associated percentages. Then, comparisons were conducted 
using paired Student’s t-test or Wilcoxon test if the assumptions 
of t-test were not met.
Without a gold standard, LCMs were applied to create an 
unobserved (“latent”) variable. The latent variable represents 
an individual’s true unobserved disease status, used subse-
quently as a gold standard to estimate sensitivity and speci-
ficity of various diagnostic criteria for RBD. This method was 
applied using poLCA, a package available in R, which uses 
expectation-maximization and Newton-Raphson algorithms 
to find maximum likelihood estimates of the model param-
eters, as described previously [39]. The observed variables used 
in these models were: (1) history of dream enactment behav-
iors (“history”), (2) vPSG-documented REM sleep-related motor 
behaviors (“video”), and (3) RSWA according to the proposed 
cutoff derived from the SINBAR scoring method. We evaluated 
best fit using Akaike information criterion and Bayesian infor-
mation criterion. Sensitivity analysis was also realized with 
an alternative RSWA cutoff derived from the Montréal scoring 
method. Concordance between each criterion for RBD and the 
classification obtained with latent class method was then as-
sessed with percent agreement and Cohen’s kappa coefficient 
(K). Finally, sensitivity (Se), specificity (Sp), positive predictive 
value (PPV), and negative predictive value (NPV) were calcu-
lated to assess diagnostic performance of each diagnostic 
criterion for RBD. These measures were expressed with 95% 
confidence interval.
The same statistical assessment (percent agreement, Cohen’s 
K, Se, Sp, PPV, and NPV) was also used for the two screening 
questionnaires, namely RBD1Q and RBDSQ, administered indi-
vidually or together.
Finally, we assessed the sensitivity and specificity of RSWA 
threshold for the diagnosis of RBD in PD. Patients with history of 
dream enactment behaviors and/or vPSG-documented behav-
iors were included in the analysis together with control subjects 
and PD patients without neither history nor vPSG-recorded 
behaviors. A  receiver operating characteristic (ROC) curve was 
generated to assess the accuracy of RSWA parameter to discrim-
inate patients having both history of dream enactment behav-
iors and vPSG-documented motor behaviors from those who 
have not. The area under the ROC curve was presented with a 
95% confidence interval obtained by the technique of DeLong 
et al. [40]. Finally, in order to study the “optimal” threshold value 




Of the original 128 patients, 17 patients were excluded from 
analysis, 4 of them because of technical reasons, 11 of them had 
none or insufficient (<5min) REM sleep during vPSG, and 2 of 
them showed an AHI ≥ 15/h.
Thus, the latent class analysis was performed in 111 PD pa-
tients (67 male, mean age: 65.8 ± 8.5 years). Figure 1 summarizes 
the flow chart of this study.
A total of 15 patients were treated with drugs known to po-
tentially increase RSWA, namely 10 patients with SSRI and 5 
patients with beta-blockers. On the other hand, nine patients 
were taking clonazepam, two patients were taking atypical 
neuroleptics, and one was taking melatonin.
Twenty-five age- and sex-matched control subjects without 
vPSG abnormalities were enrolled (12 male, mean age 61.5  ± 
13.7 years).
The clinical and demographic features of patients and 
controls are summarized in Table 1.
Polysomnographic results and RSWA analysis
Polysomnographic results in PD patients and controls are re-
ported in Table  2. Percentage and duration of REM sleep were 
significantly lower in PD patients compared to controls. Both the 
Figure 1. Flow chart of the present study.
Table 1. Clinical and demographic features of PD patients and 
controls
PD (n = 111) Controls (n = 25)
Males* 67 (60.4) 12 (48.0)
Age (years)* 65.8 ± 8.5 61.5 ± 13.7
Bed partner 55/83 (66.3) 17/25 (68)
PD duration (years) 7.9 ± 5.0 NA
H&Y stage 2.0 ± 0.7 NA
UPDRS III 17.8 ± 10.0 NA
UPDRS-tot 33.4 ± 17.5 NA
MoCA 25.4 ± 3.6 NA
LEDD (mg) 748.9 ± 454.0 NA
DA-LEDD (mg) 119.3 ± 117.1 NA
SSRI 10 (9.0) 0 (0.0)
Beta-blockers 5 (4.5) 0 (0.0)
Clonazepam 9 (8.1) 0 (0.0)
Neuroleptics 2 (1.8) 0 (0.0)
Melatonin 1 (0.9) 0 (0.0)
Data are presented as frequencies (associated percentage) or as mean ± 
standard deviation. PD: Parkinson’s disease; HC: healthy controls; H&Y: 
Hoehn and Yahr; UPDRS III: Unified Parkinson’s disease rating scale III; 
MoCA: Montréal Cognitive Assessment; LEDD: levodopa equivalent daily 
dose; DA-LEDD: dopamine-agonist levodopa equivalent daily dose; SSRI: 
selective serotonin reuptake inhibitor; NA: not applicable.
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total number and the index of PLMS were significantly higher in 
PD patients than in controls.
For the manual quantification of RSWA, a total of 8,553 30-s 
REM sleep epochs, 85,380 3-s REM sleep mini-epochs, and 127,676 
2-s REM sleep mini-epochs of REM sleep have been analyzed.
A total of 77 30-s REM sleep epochs, a total of 788 3-s epochs 
(0.9%), and 1,154 2-s REM sleep mini-epochs (0.9%) were ex-
cluded from the analysis because of the presence of respiratory-
related arousal EMG activity.
The RSWA parameters obtained in PD patients and controls 
are shown in Table  3. All RSWA parameters were significantly 
higher in PD patients than in controls.
Sixty-six percentage of PD patients have a bed partner. No 
relationship was found between having a bed partner and the 
presence of the criterion “history” of RBD. Indeed, a positive 
history of RBD was found in 60% of patients with bed partner 
versus in 54% of patients without bed partner (p = 0.58).
Latent class model
The LCM analysis allows to identify patients considering their 
characteristics, namely history of dream enactment behaviors, 
vPSG-documented REM sleep-related behaviors, and RSWA, as 
having RBD (class 1) or not having RBD (class 2).
According to the best LCM-derived model, the criterion 
“history” showed 85.5% of sensitivity, 95.2% of specificity, and 
Cohen’s K of 0.78; the criterion “video” showed 88.4% of sensi-
tivity, 95.2% of specificity, and Cohen’s K of 0.81; the criterion 
“RSWA” showed 94.2% of sensitivity, 88.1% of specificity, and 
Cohen’s K of 0.83 using the SINBAR cutoff “any chin + FDS 30-s,” 
while using the Montréal cutoff, RSWA showed a sensitivity of 
88.4%, a specificity of 88.1%, and Cohen’s K of 0.75. The concomi-
tant presence of both “history” and “video” showed 73.9% of sen-
sitivity, 100% of specificity, 100% of PPV, and Cohen’s K of 0.68.
Using the SINBAR cutoff “any chin + FDS 30-s” to define RSWA, 
patients classified as having RBD according to the LCM analysis, 
showed 82.6% probability to have “history” of RBD, 85.7% to have 
motor behaviors on vPSG, and 92.2% to have RSWA. Indeed, ac-
cording to this model, patients having both history of RBD and 
presence of motor behaviors on vPSG, but without RSWA, also re-
ferred as “provisionally diagnosed with RBD” according to ICSD-3 
criteria, are classified as having RBD, so that the percentage of 
RSWA in the RBD group may not be equal to 100%. Conversely, pa-
tients with either RBD history (n = 6, 5.1%) or vPSG-documented 
behaviors (n = 6, 5.1%) and without RSWA have been classified 
as not having RBD. Likewise, patients showing only RSWA, but 
without neither history nor vPSG-documented motor behaviors, 
have been identified as not having RBD.
Similarly, using Montréal’s cutoffs to define RSWA, patients 
classified as RBD showed 83.3% likelihood to have a history of 
RBD, 84.7% to have motor behaviors on vPSG, and 86.3% to have 
RSWA. According to this model, patients showing only history 
of RBD, or both history and video-documented behaviors, but 
without RSWA, have been classified as having RBD. On the other 
hand, patients showing vPSG-documented motor behaviors 
without RSWA have been classified as not having RBD.
The LCM with RSWA defined by the SINBAR cutoff “any chin + 
FDS 30-s” was found to be the best model, with the lowest Akaike 
and Bayesian information criteria (AIC  =  355 and BIC  =  374, 
whereas AIC = 363 and BIC = 393 with a model with three latent 
classes). According to this model, RBD was diagnosed in 69 pa-
tients (62.2%) having either “history” or “video” with RSWA; or 
showing both “history” and “video” without RSWA. Table 4 sum-
marizes the LCM results.
In a separate analysis, we considered only PD patients 
(n  =  90) who were free of drugs that can potentially affect 
RSWA (namely antidepressants, beta-blockers, clonazepam, or 
melatonin). According to this LCM, PD patients having either 
at least “history,” or having “RSWA” and “video” (n  =  56; 62%) 
were classified as having RBD. Actually, untreated patients have 
a reduced, although not significant, frequency of “history” (53% 
vs. 62%) and the presence of RSWA (60% vs. 76%), while they 
have the same frequency of video-recorded behaviors (57% in 
both groups). Globally, untreated patients more often lacked the 
three criteria compared to the treated patients (32% vs. 19%, 
p = 0.035).
RSWA threshold determination
A sensitivity analysis has been performed considering different 
thresholds of RSWA (expressed by “any chin EMG + FDS 30-s” 
activity) ranging from 25% to 28%, leading to identical results. 
A ROC curve was generated to assess the accuracy of the RSWA 
to discriminate patients having both history of dream enact-
ment behaviors and vPSG-documented motor behaviors from 
those who have not, finding area under the curve (AUC) at 0.95 
[95% CI: 0.92; 0.99]. The optimal threshold value of 27% of any 
chin EMG + FDS 30-s showed 90.4% [95% CI: 81.2; 96.1] of sen-
sitivity and 92.1% [95% CI: 82.4; 97.4] of specificity. Analysis in 
untreated patients (n = 90) led to similar results: the AUC was 
Table 2. Polysomnographic features of PD patients and controls
PD (n = 111) Controls (n = 25) P
TBT (min) 465.7 ± 60.3 490.6 ± 71.6 0.23
TST (min) 329.7 ± 60.3 379.1 ± 81.2 0.06
Sleep efficiency (%) 77.6 ± 14.4 75.1 ± 15.8 0.21
WASO (min) 96.7 ± 74.4 71.6 ± 61.8 0.23
N1 (%) 9.6 ± 7.4 9.5 ± 6.6 0.93
N2 (%) 57.1 ± 13.6 55.3 ± 11.5 0.62
N3 (%) 21.4 ± 12.9 17.9 ± 9.5 0.24
REM (%) 11.7 ± 6.8 17.4 ± 4.3 <0.001*
REM (min) 38.8 ± 24.7 66.9 ± 23.0 <0.001*
PLMS (n) 121.5 ± 142.8 65.6 ± 71.6 0.03*
PLMS index 25.2 ± 33.6 12.5 ± 15.8 0.03*
AHI 4.7 ± 7.6 4.9 ± 9.4 0.92
Data are presented as mean ± standard deviation. TBT: total bed time; TST: total 
sleep time; WASO: wake after sleep onset; N1: NREM sleep stage N1; N2: NREM 
sleep stage N2; N3: NREM sleep stage N3; PLMS: periodic leg movements during 
sleep; AHI: apnea/hypopnea index.
*p < 0.05.
Table 3. REM sleep EMG tone parameters in PD patients and controls
PD (n = 111) Controls (n = 25) P
Tonic EMG chin 30-s (%) 38.9 ± 31.2 3.2 ± 6.7 <0.001
Phasic EMG 2-s (%) 9.5 ± 9.4 5.7 ± 9.2 <0.001
Phasic EMG chin 3-s (%) 10.3 ± 8.9 4.5 ± 3.9 <0.001
Any EMG chin + FDS 30-s (%) 43.6 ± 31.2 3.8 ± 6.8 <0.001
Data are presented as mean ± standard deviation. PD: Parkinson’s disease; EMG: 
electromyography; 30-s: 30 seconds epoch; 2-s: 2 seconds mini-epochs; 3-s: 3 sec-
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0.97 [95% CI: 0.94; 1]. The optimal threshold value of 27% of any 
chin EMG + FDS 30-s showed a sensitivity of 92.9% [95% CI: 84.5; 
97.1] and a specificity of 94.9% [95% CI: 85.1; 99.4].
Figure  2 resumes the ROC analysis results in the whole 
sample.
RBD screening questionnaires
Ninety-seven patients fulfilled the RBD1Q and the RBDSQ, be-
fore a sleep-focused interview. Table 5 reports the performance 
of screening questionnaires.
RBDSQ administered prior the clinical interview showed 55.7% 
of sensitivity and 71.4% of specificity, with a PPV of 77.3% and NPV 
of 48.1%. On the other hand, the RBD1Q showed 67.7% of sensitivity, 
82.9% of specificity, with 87.5% of PPV and 59.2% of NPV. Combining 
RBD1Q and RBDSQ led to 72.6% of sensitivity, 65.7% of specificity, 
78.9% of PPV, and 57.5% of NPV, but did not significantly increase dis-
criminant power in detecting RBD in PD patients. Besides, the two 
questionnaires showed a poor agreement with Cohen’s K of 0.37, 
probably because they explore different symptoms dimensions.
Discussion
To the best of our knowledge, this is the first study assessing, in 
a large cohort of PD patients, whether the ICSD-3 diagnostic cri-
teria for RBD published by the AASM are appropriate in patients 
with PD [35, 41(p3)]. Indeed, current diagnostic criteria for RBD 
as defined by the AASM are mainly based on findings in I-RBD 
population.
According to the best latent class-derived model, patients have 
been classified as having RBD if showing either “history” or “video” 
with RSWA; or showing both “history” and “video” without RSWA. 
Using both SINBAR and Montréal scoring methods, RSWA cri-
terion showed the highest sensitivity in identify RBD, so reducing 
the risk of false negative. Similarly, concomitance of history of RBD 
and vPSG-documented behaviors, regardless to presence of RSWA, 
presented the highest specificity, hence reducing to zero the risk 
of false positive. On one hand, these results highlight the import-
ance of quantification of RSWA in detecting the true no-RBD pa-
tients. However, results of the present study suggest that, in those 
PD patients who have both a clear history of RBD and presence 
of REM sleep video-recorded behaviors, RSWA assessment is not 
mandatory for the diagnosis of RBD.
As a matter of fact, a recent study on de novo PD patients, 
longitudinally assessed by vPSG, has found that subjects with 
REM sleep associated motor behaviors not fulfilling RSWA diag-
nostic criterion (e.g. not exceeding the validated threshold), 
referred as “provisional RBD” according to ICDS-3 at base-
line, developed a full-blown RBD after 2  years follow-up [42]. 
Thus, REM sleep behavioral events not associated with RSWA 
should be considered as “prodromal” RBD. On the other hand, 
a study quantifying RSWA in 49 iRBD who eventually develop a 
neurodegenerative disorder found low levels of mentalis EMG 
activity, not reaching the published cutoffs, in 18% of these pa-
tients, highlighting the central role of the audiovisual detection 
of abnormal motor behaviors during REM sleep in performing 
the diagnosis of iRBD [43].
In light of these results, the visual inspection of vPSG may be 
crucial to detect all range of REM behavioral events. Nevertheless, 
minor movements, like twitching or jerking, may be not easily 
discernable, especially if patients sleep with sheets or blanket. 
Therefore, it is advisable that vPSG should be performed without 
blanket or at least with light sheets.
LCM performed in PD patients free of drugs that can modify 
RSWA led to different results, namely 56 (62%) PD patients 
having either at least “history,” or having “RSWA” and “video” 
were classified as RBD. One may hypothesize that this may 
be due to the lower frequency of clinical and PSG manifest-
ations in these patients during one-night in-lab PSG recording. 
Conversely, treated patients more often fulfill the three criteria 
Figure 2. Receiver operating characteristic curve generated for RSWA, consid-
ering RBD those patients with RSWA (SINBAR cutoff “any chin + FDS 30-s”), plus 
“history” and/or “video” and those patients without RSWA but with both “his-
tory” and “video.” No RBD included healthy controls together with PD patients 
classified as no-RBD. AUC: area under the curve.
Table 4. Latent class model analysis
PDRBD− (n = 42) PDRBD+ (n = 69) PA Kappa Se [95% CI] Sp [95% CI] PPV [95% CI] NPV [95% CI]
History 2 (4.8%) 59 (85.5%) 89.2% 0.78 85.5 [75.0; 92.8] 95.2 [83.8; 99.4] 96.7 [88.7; 99.6] 80.0 [66.3; 90.0]
Video 2 (4.8%) 61 (88.4%) 91.0% 0.81 88.4 [78.4; 94.9] 95.2 [83.8; 99.4] 96.8 [89.0; 99.6] 83.3 [69.8; 92.5]
History + video 0 (0.0%) 51 (73.9%) 83.8% 0.68 73.9 [61.9; 83.7] 100 [91.6; 100] 100 [93.0; 100] 70.0 [56.8; 81.2]
Any chin + FDS (30-s) 5 (11.9%) 65 (94.2%) 91.9% 0.83 94.2 [85.8; 98.4] 88.1 [74.4; 96.0] 92.9 [84.1; 97.6] 90.2 [76.9; 97.3]
Montréal 5 (11.9%) 61 (88.4%) 88.3% 0.75 88.4 [78.4; 94.9] 88.1 [74.4; 96.0] 92.4 [83.2; 97.5] 82.2 [67.9; 92.0]
PDRBD−: Parkinson’s disease patients without REM sleep behavior disorder; PDRBD+: Parkinson’s disease patients with REM sleep behavior disorder; Se: sensitivity; 








niversity of Torino user on 09 M
ay 2020
Figorilli et al. | 7
and only 19% of treated patients versus 32% of untreated pa-
tients fulfill no criteria at all. In the present study, we choose to 
consider the whole sample of patients regardless to the treat-
ment, since we believe that this is representative of the popula-
tion consulting a movement disorders or a sleep disorders clinic. 
Futures studies should be carried out with sufficient sample size 
to explore this possible treatment effect.
RSWA is a core feature of RBD diagnosis. In the present study, 
current diagnostic cutoff of RSWA included in the ICSD-3 [41] 
(i.e. ≥27% of “any chin EMG + FDS 30-2) [20, 41(p3)] was found to 
be optimal in our large cohort of PD patients, as shown by the 
ROC curve analysis. The same result was obtained in the sub-
group of PD patients free of drugs that can affect muscle tone 
during REM sleep. Besides, sensitivity analysis has been per-
formed considering different thresholds of RSWA (any chin EMG 
+ FDS 30-s) ranging from 25% to 28%, leading to identical results.
In the absence of vPSG recording, screening tools are available 
to detect the presence of clinical probable RBD. As well as clin-
ical and PSG diagnostic criteria, these screening questionnaires 
have been mainly validated in I-RBD patients consulting a sleep 
clinic, showing a very good sensitivity and specificity [25, 26]. This 
high sensitivity was probably due to the characteristics of this 
population, who were seeking medical attention for their sleep 
problem, and were aware of their RBD condition [26]. Nomura and 
colleagues [34] evaluated the validity of RBDSQ in 45 PD patients 
finding a sensitivity of 84% and specificity of 96% in detecting RBD. 
However, the clinical setting of that study potentially leading to re-
ferral bias (movement disorder vs. sleep clinic) was not specified.
Recently, Stiasny-Kolster and colleagues have assessed the 
diagnostic value of the RBD screening questionnaire in two dif-
ferent samples of patients with PD consulting a sleep clinic, 
one of which included patients who underwent a RBD-focused 
interview prior to administration of RBDSQ, whereas the other 
underwent the screening questionnaire during routine workup 
[44]. The authors found that diagnostic value of the RBDSQ 
strongly depends on the clinical setting and may be prejudiced 
by the individual’s awareness on RBD. Moreover, cultural or lin-
guistic issues may play a role, since a cutoff value of ≥8, showing 
a sensitivity of 83% and a specificity of 82%, was proposed for 
the Italian version of RBDSQ [45]. However, the authors of this 
study did not specify whether patients had I-RBD or RBD asso-
ciated with PD, a detail that seems to be crucial to evaluate the 
usefulness of screening questionnaires [45].
In the present study, both the RBDSQ and the RBD1Q ad-
ministered prior the clinical interview showed moderate sensi-
tivity and specificity, with no statistical difference between the 
two. Combined RBD1Q and RBDSQ did not perform significantly 
better in detecting RBD in PD patients. Besides, the two ques-
tionnaires showed a poor agreement with Cohen’s K of 0.37, 
probably because they explore different symptoms dimensions. 
It has to be noted that a cutoff value of ≥6 was employed also for 
the Italian speaking subjects (n = 28 out of 128), that was below 
the cutoff value proposed in the Italian validation of the RBDSQ.
Our findings confirm the notion that RBD screening ques-
tionnaires alone are of limited usefulness in PD population. This 
is especially true in case of large sample epidemiological studies 
in PD whose results should be interpreted with caution. Also, 
our findings point out the importance of a comprehensive inter-
view focused in sleep and conducted by a neurologist expert in 
sleep medicine.
In conclusion, using the best latent class-derived model for 
diagnosis of RBD in PD, our study indicates that current RBD 
diagnostic criteria, including RSWA measures, are appropriate 
in PD population [41]. Moreover, results of the present investiga-
tion suggest that patients with PD with both history and vPSG-
documented abnormal motor and vocal events during REM sleep, 
but with RSWA values within the normal range (i.e. “provisional” 
RBD) might be considered as full-blown RBD, highlighting the 
importance of a careful audiovisual inspection in patients with 
an history of dream enactment behaviors.
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